Role of surgical staging and adjuvant treatment in uterine serous carcinoma

被引:0
作者
Frey, M. K. [1 ]
Bashir, S. [1 ]
Ward, N. M. [1 ]
Hensel, K. J. [2 ]
Caputo, T. A. [1 ]
Holcomb, K. M. [1 ]
Baergen, R. [3 ]
Gupta, D. [1 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Gynecol Oncol, Dept Obstet & Gynecol, New York, NY USA
[2] Columbia Univ, Dept Pediat, Div Infect Dis, Med Ctr, New York, NY 10027 USA
[3] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Pathol, New York, NY USA
关键词
Uterine serous carcinoma; Surgical staging; Adjuvant therapy; PAPILLARY; RADIATION; SURVIVAL; CHEMOTHERAPY; ENDOMETRIUM; UPSC;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of investigation: This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence. Materials and Methods: Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared. Results: Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043). Conclusion: In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.
引用
收藏
页码:453 / 456
页数:4
相关论文
共 26 条
[1]  
[Anonymous], INT J GYNAECOL OBSTE
[2]   Extended surgical staging for uterine papillary serous carcinoma: Survival outcome of locoregional (Stage I-III) disease [J].
Bristow, RE ;
Asrari, F ;
Trimble, EL ;
Montz, FJ .
GYNECOLOGIC ONCOLOGY, 2001, 81 (02) :279-286
[3]   THERAPEUTIC APPROACHES TO UTERINE PAPILLARY SEROUS CARCINOMA - A PRELIMINARY-REPORT [J].
CHRISTMAN, JE ;
KAPP, DS ;
HENDRICKSON, MR ;
HOWES, AE ;
BALLON, SC .
GYNECOLOGIC ONCOLOGY, 1987, 26 (02) :228-235
[4]   Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma [J].
Cirisano, FD ;
Robboy, SJ ;
Dodge, RK ;
Bentley, RC ;
Krigman, HR ;
Synan, IS ;
Soper, JT ;
Clarke-Pearson, DL .
GYNECOLOGIC ONCOLOGY, 1999, 74 (03) :385-394
[5]   Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma [J].
Einstein, Mark H. ;
Frimer, Marina ;
Kuo, Dennis Y. -S. ;
Reimers, Laura L. ;
Mehta, Keyur ;
Mutyala, Subhakar ;
Huang, Gloria S. ;
Hou, June Y. ;
Goldberg, Gary L. .
GYNECOLOGIC ONCOLOGY, 2012, 124 (01) :21-25
[6]   Uterine papillary serous carcinoma: epidemiology, pathogenesis and management [J].
Fader, Amanda Nickles ;
Boruta, David ;
Olawaiye, Alexander B. ;
Gehrig, Paola A. .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) :21-29
[7]  
FRANK AH, 1991, CANCER, V68, P1516, DOI 10.1002/1097-0142(19911001)68:7<1516::AID-CNCR2820680709>3.0.CO
[8]  
2-X
[9]  
Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
[10]  
GITSCH G, 1995, CANCER-AM CANCER SOC, V75, P2239, DOI 10.1002/1097-0142(19950501)75:9<2239::AID-CNCR2820750908>3.0.CO